PD184352 (CI-1040)_MEK的选择性抑制剂_212631-79-3_Apexbio

合集下载

胃癌二线靶向治疗方案选择

摘要：胃癌是全球范围内发病率和死亡率较高的恶性肿瘤之一。

随着靶向治疗药物的研发和临床应用，胃癌的治疗策略已经发生了显著变化。

本文旨在探讨胃癌二线靶向治疗方案的选择，分析不同靶向药物的适应症、疗效和安全性，为临床医生提供参考。

一、引言胃癌是一种常见的恶性肿瘤，其发病率在全球范围内居第5位，死亡率居第3位。

尽管近年来胃癌的治疗手段不断进步，但晚期胃癌患者的预后仍然较差。

随着分子生物学和药物研发的快速发展，靶向治疗已成为胃癌治疗的重要组成部分。

二线靶向治疗是指针对已经接受过一线化疗或化疗联合靶向治疗的胃癌患者，选择合适的靶向药物进行治疗。

二、胃癌二线靶向治疗药物1. 帕博利珠单抗（Pembrolizumab）帕博利珠单抗是一种针对PD-1的免疫检查点抑制剂，通过阻断PD-1/PD-L1通路，增强机体对肿瘤的免疫反应。

帕博利珠单抗在二线治疗中的适应症为PD-L1表达阳性的晚期胃癌患者。

2. 纳武单抗（Nivolumab）纳武单抗也是一种PD-1抑制剂，与帕博利珠单抗的作用机制相似。

纳武单抗在二线治疗中的适应症为PD-L1表达阳性的晚期胃癌患者。

3. 程序性死亡配体1（PD-L1）抑制剂PD-L1抑制剂包括阿替利珠单抗（Atezolizumab）和度伐利尤单抗（Durvalumab），它们通过阻断PD-L1与PD-1的结合，提高机体对肿瘤的免疫反应。

这些药物在二线治疗中的适应症同样为PD-L1表达阳性的晚期胃癌患者。

4. 抗VEGF抗体抗VEGF抗体包括贝伐珠单抗（Bevacizumab）、瑞格列珠单抗（Regorafenib）和安罗替尼（Anlotinib）。

这些药物通过抑制血管内皮生长因子（VEGF）信号通路，减少肿瘤血管生成，从而抑制肿瘤生长。

抗VEGF抗体在二线治疗中的适应症为晚期胃癌患者，但需根据患者的具体情况选择合适的药物。

5. 抗EGFR抗体抗EGFR抗体包括西妥昔单抗（Cetuximab）和帕尼单抗（Panitumumab）。

SMK-17在β-连环蛋白突变的癌症中选择性诱导凋亡

SMK-17,a MEK1/2-specific inhibitor,selectively induces apoptosis in b -catenin-mutated tumorsMasaki Kiga 1,2*,Ayako Nakayama 1*,Yuki Shikata 1,Yukiko Sasazawa 1,Ryo Murakami 2,Toshiyuki Nakanishi 2,Etsu Tashiro 1&Masaya Imoto 11Department of Biosciences and Informatics,Faculty of Science and Technology,Keio University,Yokohama,Japan,2Shinagawa R&D Center,Daiichi Sankyo Co.Ltd,Tokyo,Japan.Although clinical studies have evaluated several MEK1/2inhibitors,it is unlikely that MEK1/2inhibitors will be studied clinically.BRAF mutations have been proposed as a responder marker of MEK1/2inhibitors in a preclinical study.However,current clinical approaches focusing on BRAF mutations have shown only moderate sensitivity of MEK1/2inhibitors.This has led to insufficient support for their promoted clinical adoption.Further characterization of tumors sensitive to MEK inhibitors holds great promise foroptimizing drug therapy for patients with these tumors.Here,we report that b -catenin mutations accelerate apoptosis induced by MEK1/2inhibitor.SMK-17,a selective MEK1/2inhibitor,induced apoptosis in tumor cell lines harboring b -catenin mutations at its effective concentration.To confirm that b -catenin mutations and mutant b -catenin-mediated TCF7L2(also known as TCF4)transcriptional activity is a predictive marker of MEK inhibitors,we evaluated the effects of dominant-negative TCF7L2and of active,mutated b -catenin on apoptosis induced by MEK inhibitor.Indeed,dominant-negative TCF7L2reduced apoptosis induced by MEK inhibitor,whereas active,mutated b -catenin accelerated it.Our findings show that b -catenin mutations are an important responder biomarker for MEK1/2inhibitors.Constant activation of the mitogen-activated protein kinase (MAPK)pathway due to aberrant activation of receptor tyrosine kinase and due to K-Ras mutations or BRAF mutations is common in human tumors and represents a major factor in abnormal cell growth 1.Approximately 30%of all human tumors contain an activating Ras mutation 2.Oncogenic V600E mutations in BRAF have been found in 66%of melanomas and in 69%of papillary thyroid tumors 3,4.Furthermore,aberrant activation of the MAPK pathway correlates with tumor progression and poor prognosis in patients with various tumors.The constitutive expression of MEK1/2is sufficient to induce transformation 5,6.Targeting MEK1/2with small-molecule inhibitors is an attractive treat-ment strategy,as all potentially aberrant oncogenic signaling upstream is preventable 7.Furthermore,several MEK inhibitors (e.g.,PD184352/CI-1040and PD0325901)have been evaluated in clinical studies 8–10.However,MEK inhibitors have met with limited clinical success in single-agent therapy.Wnt signaling also plays a central role in cell proliferation and differentiation 11.In the absence of a Wnt stimulus,b -catenin interacts with AXIN1/2,glycogen synthase kinase-3b (GSK-3b ,encoded by GSK3B),and the adenomatous polyposis coli protein (APC).GSK-3b phosphorylates b -catenin and triggers its ubiquitination and degradation by b -Trcp 12.Activation of the Wnt pathway inhibits GSK-3b -dependent phosphorylation of b -catenin and then stabilizes b -catenin.The form of b -catenin resulting from hypophosphorylation then translo-cates to the nucleus and interacts with TCF7L2,leading to increased expression of c-Myc or cyclin D113,14.Mutations in b -catenin enhance its stability and promote the subsequent transactivation of TCF7L2;such transactivation is found in a wide variety of human tumors 15.Although MAPK and Wnt signals are important intracellular signaling pathways,the mechanism of their crosstalk is not yet fully elucidated.In this study,we classified human tumor cell lines as either sensitive or resistant to a MEK inhibitor,as determined by apoptosis induction.We show that mutated b -catenin in tumor cells promotes MEK inhibitor-induced apoptosis.Our results suggest that b -catenin mutations are a novel predictive marker of MEK inhibitors.OPENSUBJECT AREAS:CHEMOTHERAPYAPOPTOSISReceived24September 2014Accepted24December 2014Published2February 2015Correspondence and requests for materials should be addressed to M.I.(imoto@bio.keio.ac.jp)*These authors contributed equally tothis work.ResultsSMK-17inhibited cell proliferation in tumor cell lines with activated K-Ras or BRAF mutations .SMK-17was a potent and highly selective MEK1/2inhibitor with an IC 50of 62and 56nM,respectively (Figure 1A).Several studies have reported a wide range of sensitivity toward the anti-proliferative effects of MEK1/2inhibitors 16.As we have previously confirmed,MEK1/2inhibition by SMK-17without off-targeting kinases has remarkably high selectivity 17;thus,we examined the effect of SMK-17on several types of human tumor cell lines.As shown in Figure 1B,cell lines with BRAF mutations,including colo-205,SK-MEL-1,HT-29,colo-201,and A375cells,were sensitive to SMK-17.Cell lines with K-Ras mutations,such as SW480,HCT 116,SW620,LS-174T,and OVCAR-5cells,were moderately sensitive to SMK-17.Scatter plots showing the log IC 50of cell lines with mutations in the MAPK pathway,including mutations in K-Ras or BRAF,revealed that these cell lines were completely sensitive to SMK-17(Figure 1C).We similarly analyzed the effect of SMK-17in cells with mutations in the PI3K pathway (including mutations in PI3K or PTEN),p53,and the Wnt pathway including APC and b -catenin.Significant differences were not observed in cell lines harboring PI3K and p53mutations.On the other hand,there were significant differences in sensitivities between cell lines with Wnt pathway mutations and theother cell lines (Figure 1C).Similar results were obtained when another MEK inhibitor,U0126,was used instead of SMK-17(Figure 1D).SMK-17induced apoptosis in active b -catenin-mutant cell lines .We evaluated A375,HT-29,HCT 116,colo-205,and SW48cells,which are representative cell lines that are highly sensitive to SMK-17(i.e.,an IC 50of less than 2.0m M),with respect to the effect of SMK-17on the MAPK pathway,cell cycle,and apoptosis induction.SMK-17inhibited ERK1/2phosphorylation in all cell lines in a dose-dependent manner (Figure 2A),as determined by analysis of intracellular MEK1/2activity.Treatment with 1m M SMK-17,which almost completely inhibited ERK1/2phosphorylation,induced G1cell cycle arrest in BRAF-mutant A375and HT-29cells (Figure 2B).However,even at concentrations of up to 10m M,SMK-17did not induce apoptosis in BRAF-mutant A375and HT-29cells,as shown by the increase in the sub-G1population,as determined via flow cytometry (Figure 2B).On the other hand,treatment of cells with SMK-17at the minimum effective concentrations for the inhibition of ERK1/2phosphorylation induced apoptosis in BRAF-mutant colo-205and K-Ras-mutant HCT 116cell lines,as shown by the presence of cleaved PARP (Figure 2A).SMK-17-induced apoptotic cell death wasfurtherFigure 1|Anti-tumor activities of SMK-17in vitro .(A)The chemical structure of SMK-17,its IC 50values for the cell-free kinase reactions of human MEK1and MEK2,and kinase inhibition profiling on 233human kinases at 1000nM of SMK-17.(B)IC 50values for a panel of tumor cell lines harboring several oncogenic mutations treated with the MEK inhibitors,SMK-17and U0126.Cell numbers were determined 72h after compound treatment.IC 50values were calculated from dose-response curves,as described in the Materials and Methods.The figures show the differential growth inhibition pattern of the compounds against the 24tumor cell lines tested.The log y-axis shows the difference between the mean of the log IC 50for the 24cell lines and the log IC 50for each cell line.Values are the mean of three independent experiments.(C)SMK-17and (D)U0126selectively inhibit the proliferation of MAPK-mutated tumor cell lines.Scatter plots show the log IC 50of mutated cell line and the rest one in the MAPK,PI3K,p53,and Wnt pathway (in a left-to-right fashion).P values were obtained by performing a Student’s t -test for group comparisons.confirmed by the detection of a sub-G1population in HCT 116and colo-205cells (Figure 2B).However,the SW48cell line,which does not carry mutations in either the K-Ras or BRAF gene,still underwent apoptosis under conditions in which ERK1/2phosphorylation is inhibited by SMK-17(Figures 2A and 2B).These results indicate that the apoptosis-inducing ability of SMK-17is independent of the status of the MAPK pathway in tumor cells.Therefore,we focused on the differences between the cell lines that underwent either G1arrest or apoptosis by examining the b -catenin status of cells;cell lines that underwent apoptosis after SMK-17treatment commonly harbored a mutation of b -catenin activation.The dependence of SMK-17-induced apoptosis on such mutation was further explored.Other cell lines also harboring such mutation,specifically,SK-MEL-1and LS-174T cells,also underwent apoptosis when treated with SMK-17,as indicated by the increased cell popu-lation at the sub-G1peak (Figure 2C).However,DLD-1and SW620cells,which harbor a K-Ras mutation but not a mutation of b -catenin activation,did not undergo apoptosis under conditions in which the ERK1/2phosphorylation was completely inhibited by SMK-17(Figure 2C).Next,we examined whether another MEK inhibitor alsoselectively induced apoptosis in cell lines harboring activating muta-tions in b -catenin.As shown in Figure 2D,1.0m M PD184352com-pletely inhibited ERK1/2phosphorylation and induced cell cycle arrest at the G1phase in HT29cells.Similarly,PD184352also inhib-ited ERK1/2phosphorylation in DLD-1cells without leading to a significant increase in the sub-G1population (Figure 2D).On the other hand,PD184352inhibited ERK1/2phosphorylation at con-centrations of 0.3m M and higher in HCT 116cells and gradually induced a dose-dependent increase in the sub-G1population.Similar results were obtained in SW48cells,indicating that MEK inhibitors selectively induced apoptosis in cell lines harboring active mutations in b -catenin.Activating mutations in b -catenin are associated with SMK-17-induced apoptosis .To test the hypothesis that active mutations in b -catenin may be responsible for apoptosis mediated by MEK inhibitor,we transfected the active form of b -catenin (S37A,S45A)and EGFP expression plasmids into A375cells harboring wild-type b -catenin and evaluated SMK-17-induced apoptotic cell death by analyzing the levels of cleaved PARP via western blotting.AsFigure 2|MEK inhibitors selectively induced apoptosis in b -catenin-mutated cell lines.(A)SMK-17selectively induced apoptosis in b -catenin-mutated cell lines at the lowest effective concentration.Cells were treated with the indicated concentrations of SMK-17and,after 24h,cell lysates were probed for ERK1/2,phospho-ERK1/2(p-ERK1/2),cleaved PARP,and b -actin expression via western blot.(B)SMK-17induced G1arrest in b -catenin wild-type cells and apoptosis in b -catenin-mutant cells.Cells were treated with the indicated concentrations of SMK-17.After 48h,the sub-G1and G1populations were analyzed by flow cytometry.The percentage of the sub-G1population (red)is indicated in each histogram.(C)SMK-17induced apoptosis in b -catenin-mutant cells.Cells were treated with the indicated concentrations of SMK-17.After 24h,cell lysates were probed for ERK1/2and phospho-ERK1/2(p-ERK1/2)by western blot.After 48h,the sub-G1and G1populations were analyzed by flow cytometry.(D)PD184352induced apoptosis in b -catenin-mutant cells.Cells were treated with the indicated concentrations of PD184352.After 24h,cell lysates were probed for ERK1/2and phospho-ERK1/2(p-ERK1/2)by western blot.After 48h,the sub-G1and G1populations were analyzed by flow cytometry.shown in Figure 3A,expression of the active form of b -catenin did not affect SMK-17-induced inhibition of ERK1/2phosphorylation,although apoptosis was observed after SMK-17treatment in A375cells.To quantitatively detect early apoptosis and late apoptosis induced by SMK-17,active b -catenin/EGFP-transfected A375cells were stained with annexin V/APC and 7-AAD and then analyzed by flow cytometry,with the gates set to include only EGFP-positive cells.As shown in Figure 3B,SMK-17at concentrations of up to 10m M did not affect the proportion of annexin V 1/7-AAD 2cells (early apoptosis)and annexin V 1/7-AAD 1cells (late apoptosis)in control,EGFP-expressing A375cells.On the other hand,the percentage of not only early apoptotic,but also of late apoptotic A375cells expressing the active form of b -catenin increased dose-dependently.At 10m M SMK-17,22.0%of A375cells expressing active b -catenin were early apoptotic,and 46.7%were late apoptotic.In contrast 1.4%of control EGFP-expressing A375cells were early apoptotic and 0.7%were late apoptotic.These results indicate that expression of the active form of b -catenin is required for SMK-17-induced apoptosis.TCF7L2activity is related to apoptosis induced by MEK inhibitor in b -catenin-mutant cell lines .To show that SMK-17-induced apoptosis could be regulated by the enhancement of b -catenin-dependent transcriptional activation,A375cells were co-transfected with the TOPFlash and Renilla luciferase plasmids.Transfected cells were treated with 50ng/mL recombinant Wnt3a for 24h,and their luciferase activity was measured.Wnt3a was found to accelerate TCF7L2transcription in A375cells (Figure 4A).SMK-17-induced apoptosis in untreated and Wnt3a-treated A375cells was analyzed by western blotting for cleaved PARP.We found that levels of cleaved PARP increased after combination treatment with SMK-17and Wnt3a relative to levels after treatment with either agent (Figure 4B).To further confirm that TCF7L2transcriptional activity is involved in SMK-17-induced apoptosis,we next examined the effect of TCF7L2downregulation on SMK-17-induced death of HCT 116cells harboring an active mutation of b -catenin.As shown in Figure 5A,TCF7L2transcriptional activity was successfully reduced after dominant-negative TCF7L2(DN-TCF7L2)plasmid transfection (0.061to 0.033).DN-TCF7L2-transfected cells were then treated with SMK-17and stained with annexin V/APC and 7-AAD for the analysis of apoptosis via flow cytometry.SMK-17-induced apoptosis in control EGFP-expressing HCT 116cells (at 10m M SMK-17,23.2%were annexin V 1/7-AAD 2and 17.1%were annexin V 1/7-AAD 1)was greatly diminished by the expressionofFigure 3|Overexpression of the active form of b -catenin induced apoptosis in SMK-17-treated A375cells.A375cells were transfected with the control vector or with a vector for the active form of b -catenin.Transfected cells were treated with DMSO or SMK-17(1.0,3.0,and 10m M).After 48h,(A)cell lysates were probed for ERK1/2,phospho-ERK1/2(p-ERK1/2),and cleaved PARP by western blot.(B)Cells were stained with annexin V/APC and 7-AAD and then analyzed by flow cytometry,with gates set to include only EGFP-positive cells.Apoptotic cells were defined as being annexinV-positive.Figure 4|Activation of Wnt/b -catenin signaling by Wnt3a induced apoptosis in A375cells.(A)A375cells were co-transfected with the TOPFlash and Renilla luciferase plasmids.Transfected cells were treated with 50ng/mL Wnt3a for 24h,and their luciferase activity was measured.Wnt signaling activity in terms of TCF7L2transcription was monitored by using the TOPFlash/continuous Renilla luciferase assay.The ratio of the firefly luciferase intensity of TOPFlash to that of Renilla luciferase was used as an indicator of TCF7L2transcriptional activity.(B)Cells were treated with either DMSO or with 10m M SMK-17,with or without 50ng/mL recombinant Wnt3a,for 48h.Cell lysates were probed for ERK1/2,phospho-ERK1/2(p-ERK1/2),and cleaved PARP via western blot.Cleaved PARP was observed after combination treatment with SMK-17and Wnt3a.DN-TCF7L2(at 10m M SMK-17,14.8%were annexin V 1/7-AAD 1and 3.1%were annexin V 1/7-AAD 1;Figure 5B).Thus,SMK-17-induced apoptosis positively correlated with TCF7L2transcriptional activity.Involvement of c-Myc-mediated apoptosis gene expression in SMK-17-induced apoptosis of b -catenin-mutant cells .As b -catenin-mediated increase in TCF7L2transcriptional activity is involved in SMK-17-induced apoptosis,we next examined the possibility that SMK-17-induced apoptosis in b -catenin-mutant cells is mediated by c-Myc,whose promoters are directly activated by TCF7L2.To do this,HCT 116cells were transiently transfected with c-myc siRNA,and their cell viability following SMK-17treatment was examined.As shown in Figure 6A,SMK-17dose-dependently decreased both c-Myc and phosphorylated ERK1/2levels (Figure 6A).Furthermore,as the PARP cleavage and sub G1population detected by flow cytometry analysis show,silencing c-Myc expression suppressed SMK-17-induced apoptosis.Indeed,as shown in Figure 6B and 6C,Wnt3a-induced PARP cleavage and sub G1population in SMK-17-treated A375cells were also inhibited by the knockdown of c-Myc.These results indicate that c-Myc is a key regulator involved in apoptosis induced by MEK inhibitor when the Wnt pathway is activated,for example,during Wnt3a stimulation or when b -catenin is mutated.Apoptosis induction of SMK-17in b -catenin-mutated xenograft models .Because SMK-17selectively induced apoptosis in cell lines harboring activating mutations in b -catenin in vitro ,we next examined the ability of SMK-17to induce apoptosis in vivo .Active b -catenin-mutant tumor cells (SW48and colo-205cells)and wild-type b -catenin tumor cells (A375and HT-29cells)were injected subcutaneously into NOD-SCID mice (SW48cells)or nude mice (other cell lines)to establish xenograft models.SMK-17or the control vehicle was then administered by oral gavage.We confirmed the inhibitory activity of SMK-17toward intratumor MEK by monitoring levels of phosphorylated ERK1/2in SW48and A375cells in vivo after a single dose of SMK-17(Supplemental Figure S1).As shown in Figure 7A,tumor regression in response to multiple daily oral administration of SMK-17at half MTD (200mg/kg)was observed only in active b -catenin-mutant xenograft models,namely,models using SW48and colo-205cells.On the other hand,the maximum effect of SMK-17at MTD dosing (400mg/kg)was just growth inhibition of A375and HT-29cells expressing wild-type b -catenin,without significant body weight loss.TUNEL staining revealed significant apoptosis induction in SW48tumor tissues from SMK-17-treated but not in SW48tumor tissues from control mice (Figure 7B).In contrast,apoptotic cells were not observed in the SMK-17-treated A375xenograft model.DiscussionSMK-17is a highly selective inhibitor of MEK1and MEK2in a non-ATP-competitive manner,possibly because of its binding to the allosteric pocket of MEK1/217.In addition,we reported that SMK-17inhibited cell growth in colon-26and HT-29cell lines harboring highly phosphorylated MEK1/2and ERK1/217.In this study,we investigated the effect of SMK-17on several types of human tumor cells in detail.We found SMK-17to be highly effective in limiting the proliferation of tumor cells with aberrant activated MAPK pathway signaling (Figures 1B and 1C).Furthermore,tumor cells harboring BRAF mutations were found to be more sensitive to SMK-17than were tumor cells with K-Ras mutations.This is similar to results for another MEK inhibitor 18.These observations can be explained by the fact that BRAF mutations could directly influence MEK activity,as it is an immediate upstream effector of MEK,whereas Ras mutations activate additional signaling pathways that bypass MEK 19.Thus,BRAF mutations predict a cell’s sensitivity to MEK inhibition 19.Interestingly,SMK-17-sensitive BRAF-and K-Ras-mutant cells could be classified into two groups based on the fate of cells after SMK-17treatment.One contains tumor cells that undergo SMK-17-induced cell-cycle arrest (BRAF-mutant A375and HT-29cells and K-Ras-mutant SW620cells),and the other consists of tumor cells that undergo apoptosis when SMK-17inhibits the phosphorylation of ERK1/2(BRAF-mutant colo-205cells and K-Ras-mutant HCT 116and LS-174T cells).Therefore,it is difficult to predict whether SMK-17elicits cell growth inhibition or apoptosis solely on the basis of their BRAF or K-Ras mutation status.However,we also found that their sensitivity to the MEK inhibitor was closely related to the status of mutations in canonical Wnt/b -catenin signaling (Figure 1C).Indeed,we found that a common feature of tumor cells that undergo apoptosis following SMK-17treatment is the presence of an active mutation in b -catenin.Mutations in b -catenin in these cells involve the deletion or the exchange of serine and threonine residues at positions 45and 33(HCT 116cells:S45deletion,SW48cells:S33Y,LS-174T cells:S45F,and SK-MEL-1cells:S33C),thus interfering with itsefficientFigure 5|Expression of DN-TCF7L2reduced SMK-17-induced apoptosis in HCT 116cells.HCT 116cells were transfected with DN-TCF7L2.(A)Luciferase activity was monitored through co-transfection with the TOPFlash and Renilla luciferase plasmids.(B)HCT 116cells expressing DN-TCF7L2were treated with the indicated concentrations of SMK-17for 48h and stained with annexin V/APC and 7-AAD.Cells were analyzed by flow cytometry with gates including only EGFP-positive cells.ubiquitination and degradation by the proteasome 20.Furthermore,colo-201and colo-205cells showed a homozygous A-to-G missense transition mutation at codon 287in exon 6,resulting in the substi-tution of serine for asparagine (N287S).Therefore,among the tumor cells tested,only active b -catenin mutants,irrespective of the status of BRAF or K-Ras mutation,underwent apoptosis after treatment with the MEK inhibitor at minimum effective concentrations for the inhibition of ERK1/2phosphorylation.A requirement for an active b -catenin mutation for SMK-17-induced apoptosis was confirmed by the following findings:1)SMK-17induced apoptosis in A375cells expressing the active form of b -catenin and harboring wild-type b -catenin (Figure 3A and 3B).2)Stimulation of Wnt/b -catenin signaling with Wnt3a enhanced the ability of SMK-17to induce apoptosis in A375cells (Figures 4A and 4B).3)Inhibition of b -catenin signaling by the expression of DN-TCF7L2suppressed SMK-17-induced apoptosis in HCT 116cells harboring an active b -catenin mutation (Figures 5A and 5B).These results are consistent with the findings of another study show-ing that apoptosis mediated by targeted BRAF inhibition in mela-noma is dependent on b -catenin 21.What remains unclear is the mechanism by which SMK-17selec-tively induced apoptosis in cell lines harboring active,mutated b -catenin.Through interaction with TCF/LEF transcription factors,b -catenin promoted the expression of Wnt target genes such as those for c-Myc ,cyclin D2,and CD4422.There is now strong evidence that increased c-Myc expression is a key component of Wnt signaling,which regulates the expression of genes involved in diverse cellularprocesses such as apoptosis,cell cycle progression,cell growth,and DNA replication 23,24.Furthermore,c-Myc protein is known to be phosphorylated and stabilized by ERK1/225;indeed,inhibition of ERK phosphorylation by SMK-17led to decreased c-Myc expression (Figure 6A).Nevertheless,we confirmed that c-Myc leads to SMK-17-induced apoptosis in tumor cells harboring b -catenin mutations;c-Myc knockdown inhibited SMK-17-induced apoptosis not only in b -catenin-mutant HCT 116cells,but also in Wnt3a-stimulated A375cells.We also determined which c-Myc-mediated,apoptosis-related proteins contributed to SMK-17-induced apoptosis in tumor cells harboring b -catenin mutations.Several studies demonstrated the involvement of BIM in apoptosis induced by RAF or MEK inhib-itor 21,26–31.BIM,the Bcl-2homology domain 3-only (BH3-only)pro-tein,is known to bind and inhibit prosurvival Bcl-2family members.Expression of BIM is regulated by c-Myc 26,32and is inhibited by BRAF-MEK-ERK signaling in mouse and human melanocytes,as well as in human melanoma cells 33.Therefore,inhibition of BRAF-MEK-ERK signaling increases the levels of BIM expression,inducing cells to undergo apoptosis.We also found that SMK-17induced an increase in BIM expression levels upon inhibition of ERK phosphor-ylation in b -catenin-mutant HCT 116,SW48,and colo-205cells (Supplemental Figure S2).However,knockdown of BIM failed to suppress SMK-17-induced apoptosis in all cell lines tested (data not shown).Therefore,proteins related to c-Myc-mediated apopto-sis other than BIM might be responsible for the active b -catenin-mediated apoptosis induced by SMK-17.Furthermore,consistentFigure 6|Involvement of c-Myc in SMK-17-induced apoptosis.(A)HCT 116cells were transfected with control or c-myc siRNA.Transfected cells were treated with the indicated concentrations of SMK-17for 24h.Western blotting of cell lysates showed reduced expression of phospho-ERK1/2(p-ERK1/2)and c-Myc protein and increased expression of cleaved PARP.(B)A375cells were transfected with control or c-myc siRNA.Transfected cells were treated with the indicated concentrations of SMK-17in the presence or absence of 20ng/mL Wnt3a for 24h.The expression of ERK1/2,p-ERK1/2,c-Myc,active b -catenin,and cleaved PARP was detected by western blotting.(C)A375cells were transfected with control or c-myc siRNA.Transfected cells were treated with the indicated concentrations of SMK-17in the presence or absence of 20ng/mL Wnt3a for 48h.The apoptosis induction was detected by flow cytometry analysis after cytological staining using PI.with the previous report 34,c-Myc protein expression in b -catenin mutated tumor cells seems to be higher than in b -catenin/APC wild-type tumor cells (Supplemental Figures S3A &B).On the other hand,the amount of c-Myc mRNA seemed to not correlate with the tran-scriptional activity of TCF7L2(Supplemental Figure S3C).Moreover,c-Myc protein expression had no increase in level in Wnt3a-stimulated A375cells (Figure 6B).Therefore,the link between TCF7L2and c-Myc is still controversial,and although knockdown of c-Myc inhibited SMK-17-induced apoptosis,we can-not exclude the possibility that another target protein of the canon-ical Wnt pathway apart from c-Myc is responsible for apoptosis induced by the MEK inhibitor.In this study,we used three APC-mutant colorectal tumor cells,namely,SW480,SW620,and DLD-1cells.SW480and SW620cells have a mutant version of the APC tumor suppressor gene,which causes premature termination of the protein at amino acid 13335,36.Codon 1416of the APC gene is mutated,and the other allele is lost in DLD-1cells,resulting in constitutively active TCF/LEF 37.b -catenin and APC mutations appear to be mutually exclusive,possibly reflect-ing the fact that both components act in the same pathway.Nevertheless,SMK-17induced cell death in SW480cells and in b -catenin-mutant cells,but not in SW620or DLD-1cells (Supplemental Figure S4).SW480and SW620cells are two colon tumor cell lines established from the same patient although they have different metastatic potential 38.They are well-characterized and rep-resent the differing features of primary and metastatic sites 39.Indeed,we found that expression levels of survivin,an anti-apoptotic protein,was significantly higher in SW620than in SW480cells (Supplemental Figure S4);this difference in survivin expression levels may explain why SW620but not SW480cells are resistant to SMK-17-induced apoptosis.On the other hand,SMK-17did not inhibit cell growth or apoptosis in DLD-1cells.DLD-1cells expressed high amounts of ERK1/2protein,although its phosphor-ylation level was quite low (Supplemental Figure S4).Therefore,it is possible that proliferation of DLD-1cells is independent of the MEK/MAPK pathway.Thus,although we do not know at present why b -catenin mutations,but not APC mutations,could predict a cell line’s sensitivity to MEK inhibitors,we found that TCF7L2transcriptional activity was higher in APC mutants than in b -catenin mutants (Supplemental Figure S5).This difference may affect the balance of c-Myc-induced expression of pro-apoptotic and anti-apoptotic pro-tein,thus regulating tumor cell survival.Therefore,moderatelyenhanced TCF7L2activity that is regulated by b -catenin mutations might be required for apoptosis induced by MEK inhibitor.Another possible explanation is that although tumor initiation by either loss of APC function or oncogenic b -catenin mutations is functionally equi-valent,the APC gene may have other functions,namely the ability to capture the kinetochore in the establishment of the mitotic spindle,a loss which underlies malignant progression,therefore,mutations in APC are responsible for chromosomal instability,and are independ-ent of their roles in Wnt signal transduction 40.Chromosome instab-ility will then confer a mutant phenotype,allowing further malignant progression through numerical and structural chromosomal rear-rangements.Thus APC mutation will accumulate mutations in other genes including pro-and anti-apoptotic genes,allowing cells to be resistant to MEK inhibitors.Thus,because of the diverse phenotypes produced by gene instability,it appears challenging to predict the sensitivity of APC mutant cells to MEK inhibitors.To link these findings to a clinically relevant model,we conducted in vivo studies using active b -catenin-mutant xenograft models.Significant tumor regression without any severe toxicity was observed in b -catenin-mutant SW48and colo-205cells in response to daily oral administration of SMK-17(Figures 7A and 7B).At present,MEK inhibitors have been evaluated in both preclinical and clinical studies as a potential therapeutic option for patients with melanomas carrying the BRAF V600-mutation;however,single-agent efficacy has been limited.Therefore,rational combination strategies using MEK inhibitors with other molecularly targeted drugs are expected to lead to greater efficacy.For example,several studies have reported crosstalk between Wnt/b -catenin and MAPK signaling 41,42.Accordingly,the combination of MEK blockade and Wnt pathway modulation has shown synergistic anti-proliferative effects in both in vitro and in vivo preclinical colorectal tumor models 43.However,we report in this study that a MEK inhibitor alone could induce signifi-cant tumor regression in b -catenin-mutant xenograft models.As b -catenin is mutated in up to 10%of all sporadic colon carcinomas resulting from point mutations or in-frame deletions of serine and threonine residues phosphorylated by GSK3b 44,our findings support the clinical use of MEK inhibitors as single agents for patients with colorectal carcinoma carrying active b -catenin mutations.On the other hand,studies with patient cohorts have been reported to determine whether active Wnt signals correlate with clinical responses to the BRAF inhibitor,and it was reported that increased nuclear b -catenin in biopsies is associated withdecreasedFigure 7|Antitumor activities of SMK-17in vivo .(A)SMK-17induced tumor regression and apoptosis in b -catenin-mutated cell lines in vivo .SMK-17suspensions and the vehicle control (0.5%MC)were orally (po)administered at 10mL/kg once daily.(B)Apoptosis induced by SMK-17in tumors.TUNEL staining results were obtained from tumors from xenograft mice 24h after the final oral administration of SMK-17(q.d.32days).Each indicated score (%)was the mean ratio of the apoptotic cells in the tissue slices from 4independent tumor-bearing mice.。

Roscovitine (Seliciclib,CYC202)选择性的CDK抑制剂CAS号186692-46-6生物活性数据

不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）
小鼠
大鼠
兔
豚鼠
仓鼠
狗
重量 (kg)
0.02
0.15
1.8
0.4
0.08
10
体表面积 (m2)0.Fra bibliotek070.025
0.15
0.05
0.02
0.5
Km 系数
3
6
12
8
5
20
动物 B的Km系数动物 A (mg/kg) = 动物 B (mg/kg) ×
生物活性
Roscovitine (Seliciclib,CYC202)是一种有效的，选择性的CDK抑制剂，作用于Cdc2， CDK2和CDK5时，IC50分别为0.65 μM， 0.7 μM和0.16 μM，对CDK4/6几乎没有抑制效果。Roscovitine作用于细胞周期蛋白依赖性激酶具有高效性和高度选择性，作用于cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E和cdk5/p53时IC50分别为 0.65,0.7,0.7和0.16 μM。纳摩尔级Roscovitine作用于海星卵母细胞和海胆胚胎，可逆抑制在前中期间转变, 在体外作用于非洲爪蟾卵提取物，抑制M期促进因子活性和体外DNA合成,且抑制哺乳动物细胞系增殖，IC50为16 μM。浓度为7.5, 12.5和 25 mM的 Roscovitine作用于肾小球系膜细胞,导致CDK2活性分别降低25,50% 和 100%，这种作用存在剂量依赖性。
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Raje N, et al. Blood. 2005 Aug 1;106(3):1042-7. PMID: 15827128.

MAPK信号通路——肝棘球蚴病治疗新靶点

.ＭＡＰＫ信号通路———肝棘球蚴病治疗新靶点董琳琳１，芦永良２，鄂维建２，张　翔２，赵玲莉２１青海大学临床医学院，西宁８１００００；２青海大学附属医院检验科，西宁８１００００摘要：ＭＡＰＫ信号通路可介导多种细胞因子参与炎症、癌症、免疫紊乱和神经退行性疾病等过程，其在肝棘球蚴病发生发展过程中也发挥重要作用。

本文回顾了ＭＡＰＫ信号通路的结构及调节过程，重点阐述了肝棘球蚴病中ＭＡＰＫ信号通路的作用，即ＭＡＰＫ信号通路在肝棘球蚴病中存在虫体与宿主的双重激活，参与了疾病的发生、发展过程，并对其治疗产生影响，以ＭＡＰＫ信号通路为靶点的药物治疗有望成为肝棘球蚴病治疗新的策略。

关键词：棘球蚴病，肝；丝裂原激活蛋白激酶类；ＭＡＰ激酶信号系统基金项目：青海省科技基础研究计划项目（２０１８－ＺＪ－７５７）ＴｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙ：ＡｎｅｗｔａｒｇｅｔｆｏｒｔｈｅｔｒｅａｔｍｅｎｔｏｆｈｅｐａｔｉｃｅｃｈｉｎｏｃｏｃｃｏｓｉｓＤＯＮＧＬｉｎｌｉｎ１，ＬＵＹｏｎｇｌｉａｎｇ２，ＥＷｅｉｊｉａｎ２，ＺＨＡＮＧＸｉａｎｇ２，ＺＨＡＯＬｉｎｇｌｉ２．（１．ＱｉｎｇｈａｉＵｎｉｖｅｒｓｉｔｙ，Ｘｉｎｉｎｇ８１００００，Ｃｈｉｎａ；２．ＤｅｐａｒｔｍｅｎｔｏｆＣｌｉｎｉｃａｌＬａｂｏｒａｔｏｒｙ，ＴｈｅＡｆｆｉｌｉａｔｅｄＨｏｓｐｉｔａｌｏｆＱｉｎｇｈａｉＵｎｉｖｅｒｓｉｔｙ，Ｘｉｎｉｎｇ８１００００，Ｃｈｉｎａ）Ｃｏｒｒｅｓｐｏｎｄｉｎｇａｕｔｈｏｒ：ＺＨＡＯＬｉｎｇｌｉ，ｚｈａｏｌｉｎｇｌｉ６４０５２１＠１６３．ｃｏｍ（ＯＲＣＩＤ：００００－０００１－７４１２－６５９５）Ａｂｓｔｒａｃｔ：ＴｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙｃａｎｍｅｄｉａｔｅａｖａｒｉｅｔｙｏｆｃｙｔｏｋｉｎｅｓｔｏｐａｒｔｉｃｉｐａｔｅｉｎｔｈｅｐｒｏｃｅｓｓｅｓｏｆｉｎｆｌａｍｍａｔｉｏｎ，ｃａｎｃｅｒ，ｉｍｍｕｎｅｄｉｓｏｒｄｅｒ，ａｎｄｎｅｕｒｏｄｅｇｅｎｅｒａｔｉｖｅｄｉｓｅａｓｅｓ，ａｎｄｉｔａｌｓｏｐｌａｙｓａｎｉｍｐｏｒｔａｎｔｒｏｌｅｉｎｔｈｅｄｅｖｅｌｏｐｍｅｎｔａｎｄｐｒｏｇｒｅｓｓｉｏｎｏｆｈｅｐａｔｉｃｅｃｈｉｎｏｃｏｃｃｏｓｉｓ．ＴｈｉｓａｒｔｉｃｌｅｒｅｖｉｅｗｓｔｈｅｓｔｒｕｃｔｕｒｅａｎｄｒｅｇｕｌａｔｉｏｎｏｆｔｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙａｎｄｅｌａｂｏｒａｔｅｓｏｎｔｈｅｒｏｌｅｏｆｔｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙｉｎｈｅｐａｔｉｃｅｃｈｉｎｏｃｏｃｃｏｓｉｓ．ＩｔｉｓｐｏｉｎｔｅｄｏｕｔｔｈａｔｔｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙｃａｎａｃｔｉｖａｔｅｂｏｔｈｔｈｅｃｙｓｔａｎｄｔｈｅｈｏｓｔｉｎｈｅｐａｔｉｃｅｃｈｉｎｏｃｏｃｃｏｓｉｓ，ｐａｒｔｉｃｉｐａｔｅｉｎｔｈｅｄｅｖｅｌｏｐｍｅｎｔａｎｄｐｒｏｇｒｅｓｓｉｏｎｏｆｔｈｅｄｉｓｅａｓｅ，ａｎｄｅｘｅｒｔａｎｉｍｐａｃｔｏｎｉｔｓｔｒｅａｔｍｅｎｔ．ＤｒｕｇｔｈｅｒａｐｙｔａｒｇｅｔｉｎｇｔｈｅＭＡＰＫｓｉｇｎａｌｉｎｇｐａｔｈｗａｙｉｓｅｘｐｅｃｔｅｄｔｏｂｅｃｏｍｅａｎｅｗｓｔｒａｔｅｇｙｆｏｒｔｈｅｔｒｅａｔｍｅｎｔｏｆｈｅｐａｔｉｃｅｃｈｉｎｏｃｏｃｃｏｓｉｓ．Ｋｅｙｗｏｒｄｓ：Ｅｃｈｉｎｏｃｏｃｃｏｓｉｓ，Ｈｅｐａｔｉｃ；Ｍｉｔｏｇｅｎ－ＡｃｔｉｖａｔｅｄＰｒｏｔｅｉｎＫｉｎａｓｅｓ；ＭＡＰＫｉｎａｓｅＳｉｇｎａｌｉｎｇＳｙｓｔｅｍＲｅｓｅａｒｃｈｆｕｎｄｉｎｇ：ＱｉｎｇｈａｉＳｃｉｅｎｃｅＡｎｄＴｅｃｈｎｏｌｏｇｙＢａｓｉｃＲｅｓｅａｒｃｈＰｒｏｇｒａｍ（２０１８－ＺＪ－７５７）ＤＯＩ：１０．３９６９／ｊ．ｉｓｓｎ．１００１－５２５６．２０２２．０３．０４５收稿日期：２０２１－０８－０４；录用日期：２０２１－０９－３０通信作者：赵玲莉，ｚｈａｏｌｉｎｇｌｉ６４０５２１＠１６３．ｃｏｍ肝棘球蚴病是棘球蚴绦虫幼虫寄生于人体和某些动物体内，侵犯其肝脏所致的一种严重肝脏疾病［１］。

Ras_Raf_MEK_ERK信号通路与细胞命运的联系

310 中国医药生物技术 2008年8月第3卷第4期Chin Med Biotechnol, August 2008, V ol. 3, No. 4·综述·Ras/Raf/MEK/ERK 信号通路与细胞命运的联系常超细胞在接受特定的细胞外信号刺激后会产生相应的特异性生理应答。

Ras/Raf/MEK/ERK 信号级联通路是一条可被广泛激活的有丝分裂原活化蛋白激酶（mitogen-activated protein kinase，MAPK）通路，它能将细胞外信号传递入细胞核内，引起细胞内特异蛋白的表达谱变化，从而影响细胞命运。

在不同情况下激活该通路可引发细胞发生特异的甚至截然相反的应答反应[1]。

最初，关于该通路的研究大多集中在转录层面，认为在不同条件下激活的该通路可调节不同的即刻早期基因（immediate early genes，IEG）的转录表达，从而引发相应的细胞特异性应答。

但近年来随着研究的逐渐深入，人们发现几乎所有的生长因子和细胞因子都能激活同样的 IEG[2]，并逐渐将研究关注点转移至激活该通路后所导致的蛋白翻译后调节层面。

现本文就 Ras/Raf/MEK/ERK 信号级联通路对细胞生理过程影响因素的最新研究进展做一综述。

1 生物学功能Ras/Raf/MEK/ERK 信号级联通路又称 ERK 通路，本文中 MEK 仅指 MEK1/2，ERK 仅指 ERK1/2。

该通路主要由一个三级酶联功能单位构成，即 Raf、MEK、ERK 激酶依次被磷酸化激活。

在生理状态下，ERK 是 MEK 的唯一下游底物，表明 MEK 及 ERK 在该通路中具有重要地位，激活后的 ERK 通过磷酸化激活一系列细胞膜表面以及细胞质、细胞核内的类似核糖体 S6 蛋白激酶（ribosomal protein S6 kinase，RSK）的蛋白激酶底物，并与之共同入核的方式促进环腺苷酸应答元件结合蛋白（cAMP responsive element binding protein，CREB）等重要转录因子的磷酸化，从而调节 IEG 如c-Fos、c-Myc、c-Jun、Egr1 等基因的转录表达[3]。

Ras_Raf_MEK_ERK信号通路与细胞命运的联系

在不同情况下激活该通路可引发细胞发生特异的甚至截然相反的应答反应[1]。

现本文就 Ras/Raf/MEK/ERK 信号级联通路对细胞生理过程影响因素的最新研究进展做一综述。

1 生物学功能Ras/Raf/MEK/ERK 信号级联通路又称 ERK 通路，本文中 MEK 仅指 MEK1/2，ERK 仅指 ERK1/2。

该通路主要由一个三级酶联功能单位构成，即 Raf、MEK、ERK 激酶依次被磷酸化激活。

激酶抑制剂(inase inhibitors)列表

期临床试验；治疗淋巴瘤已经
完成1期临床研究
BI6727（Volasertib） GSK461364 ON01910 HMN-214
PLK1
该化合物已完成一期临床试验，而对于膀胱癌的治疗已进入二期临床试验阶段
PLK1
对于实体瘤的治疗已完成一期临床试验
PLK CDK 等
对胰腺癌的治疗已进入三期临床试验阶段。
治疗费城染色体阳性慢性淋巴细胞白血病(CML) 和恶性胃肠道间质瘤 (GIST)等。已上市
Gefitinib（吉非替尼） Erlotinib（埃罗替尼） Sunitinib（苏尼替尼） Lapatinib（拉帕替尼）
Vemurafenib
EGFR
用于铂类或多紫杉醇类药物化疗失败后的局部晚期或转移性非小细胞肺癌患者的持续治疗。已上市
CDK Aurora
JNJ-7706621是新型有效的广谱CDK和Aurora激酶抑制剂；作用于CDK1和2具有高度有效性。
CDK
治疗淋巴瘤已经完成二期临床
研究；治疗成人实体瘤已经完
成一期临床研究。
UCN-01 BI2536
PLK
治疗实体瘤、急性粒细胞白血
病、非小细胞肺癌、胰腺癌、
小细胞癌、前列腺癌已完成二
Everolimus（依维莫司） Cabozantinib（XL-184）
VEGFR2 RET
广谱络氨酸激酶抑制剂。用于治疗转移性甲状腺髓样癌。已上市
mTOR
用于治疗肾细胞癌；也用于治疗乳腺癌、淋巴瘤、风湿性关节炎以及多发性骨髓瘤。已上市
Temsirolimus(西罗莫司）
Rapamycin (Sirolimus, AY22989, NSC226080）

gtf2i,通用转录因子2i

gtf2i,通用转录因子2i通用转录因子2i（General Transcription Factor 2i）是一种可以在体外培养条件下将与胚胎干细胞（ESCs）相互结合以实现自我更新和多潜能的细胞转录因子的组合。

它是由两种小分子化合物组成的，即PD0325901和CHIR99021。

PD0325901是一种选择性MEK抑制剂，能够抑制激活Mitogen-Activated Protein Kinase（MAPK）信号通路的MEK1和MEK2激酶。

MAPK信号通路参与细胞增殖和分化调控，通过抑制MEK的活性，PD0325901可以抑制MAPK信号通路的激活，从而影响细胞增殖和分化。

PD0325901能够使细胞进入稳定的细胞周期，抑制细胞分化并保持其干细胞状态。

CHIR99021是一种选择性GSK3抑制剂，能够抑制激活Glycogen Synthase Kinase 3（GSK3）的活性。

GSK3参与多种细胞进程的调控，包括细胞增殖、细胞间相互作用、信号通路传导等。

通过抑制GSK3，CHIR99021能够维持细胞的干细胞性质，促进细胞自我更新和增殖。

通用转录因子2i通过同时抑制MEK和GSK3信号通路，能够促进胚胎干细胞在体外的自我更新和长期培养。

在没有2i存在的条件下，细胞会逐渐进入分化状态，并丧失其干细胞特性。

而添加2i，特别是PD0325901和CHIR99021的组合，可以有效地保持胚胎干细胞的干细胞性质。

通用转录因子2i的应用不仅限于胚胎干细胞的研究，还可以用于其他干细胞类型的培养和维持。

例如，通过添加2i，神经干细胞（NSCs）和肌肉干细胞（MSCs）等也可以在体外进行长期培养，并保持其干细胞特性。

此外，通用转录因子2i还被广泛应用于再编程研究中。

再编程是指将体细胞转化为诱导性多能性干细胞（iPSCs）的过程。

通过将成熟的体细胞处理在含有2i的培养基中，可以促进iPSCs的形成，并提高其效率和质量。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

特别声明
产品仅用于研究，不针对患者销售，望谅解。每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
实验操作
细胞实验: 细胞系溶解方法
反应时间应用
表达 FLAG-ERK5 的 CCl39 细胞
该化合物在 DMSO 中的溶解度大于 10 mM。若配制更高浓度的溶液，一般步骤如下：请将试管置于 37℃加热 10 分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。
动物实验: 动物模型剂量
MEK1/2 的 Mg-ATP 结合位点，可以诱导非磷酸化的 MEK1/2 的构象变化导致其失活[1]。已发现 PD184352 对肿瘤有活性，它抑制鼠移植瘤模型中结肠癌的生长[1]。参考文献: [1] Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010 Feb 11;3:8. doi: 10.1186/1756-8722-3-8.
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
PD184352(也称为 CI-1040)，一个苯异羟肟衍生物，是 MEK1/2 有效的、高度选择性的抑制剂， MEK1/2 是 MAPKKs 家族的两个成员。PD184352 以非 ATP 和非 ERK1/2 竞争性方式抑制纯化的 MEK1（IC50 值 17 nM）[1]。 PD184352 结合在疏水腔中，这个疏水腔坐落在一个和其他激酶低序列同源性区域，毗邻
ApexBio Technology
运输条件:
2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenz amide
C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl
>24mg/mL in DMSO
Store at -20 Cas No.: 分子量: 分子式:
PD184352 (CI-1040) 212631-79-3 478.67 C17H14ClF2IN2O2
产品名: PD184352 (CI-1040) 修订日期: 6/30/2016
化学名:
SMILES: 溶解性: 储存条件: 一般建议:
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
MAPK Signaling
信号通路:
MEK1/2
产品描述:
注意事项
DBA/2-pcy/pcy 小鼠
口服给药，400 mg/kg，第一周每天给药，随后每隔两天给药，再给药六周。
请测试所有化合物在室内的溶解度，实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的，属于正常现象。
参考文献: [1] SQUIRES M, NIXON P, COOK S. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem. J, 2002, 366: 673-680. [2] Omori S, Hida M, Fujita H, et al. Extracellular signal–regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. Journal of the American Society of Nephrology, 2006, 17(6): 1604-1614.